Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study

BACKGROUND: Although trastuzumab (T) represents the standard of care for the adjuvant treatment of HER2‐positive early‐stage breast cancer, contrasting results are available about the cardiac toxicity associated to its use. We conducted a multiregional population‐based cohort investigation aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Franchi, Matteo, Trama, Annalisa, Merlo, Ivan, Minicozzi, Pamela, Tarantini, Luigi, Garau, Donatella, Kirchmayer, Ursula, Di Martino, Mirko, Romero, Marilena, De Carlo, Ilenia, Scondotto, Salvatore, Apolone, Giovanni, Corrao, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543336/
https://www.ncbi.nlm.nih.gov/pubmed/32770690
http://dx.doi.org/10.1634/theoncologist.2020-0216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543336/
https://www.ncbi.nlm.nih.gov/pubmed/32770690
http://dx.doi.org/10.1634/theoncologist.2020-0216

Ejemplares similares